Association of post-surgical MRD status with neoadjuvant ctDNA dynamics, genomic mutations, and clinical outcomes in patients with resectable NSCLC (R-NSCLC) from the phase 3 AEGEAN trial.
Interested in learning more about these abstracts and other trials presented at ASCO® 2025? Be sure to register for one of our licensed Best of ASCO® events in a city near you.